CB24
Financiado
Development of a natural therapeutic treatment for late-stage lung cancer patien...
Celtic Biotech Ireland has developed CB24(Crotoxin). A naturally derived receptor binding protein, delivered as monotherapy at home using infusion pumps, is hailed as a life changing treatment of Non-Small Cell Lung Cancer (NSCLC)...
Celtic Biotech Ireland has developed CB24(Crotoxin). A naturally derived receptor binding protein, delivered as monotherapy at home using infusion pumps, is hailed as a life changing treatment of Non-Small Cell Lung Cancer (NSCLC). Delivered intravenously, CB24 induces predictable and consistent apoptosis (cell death) and autophagy (degradation) in human lung carcinoma cells. CB24 outclass the competitive NSCLC treatment solutions (surgery, chemotherapy, and radiotherapy) through its efficacy, safety, minimal side-effects, easy to use home based treatment and suitability for all patients including those at stage 3 & 4.
Celtic have already proven the efficacy of CB24 through pre-clinical and FIH clinical trials.
Through the proposed 24months EIC project, the company aims to undertake Phase I Part 3 clinical trials involving 24 patients with the ultimate goal of garnering the regulatory approvals (EMA, FDA) to market the drug as a verified cancer therapeutic.
ver más
Duración del proyecto: 23 meses
Fecha Inicio: 2023-10-09
Fecha Fin: 2025-09-30
Fecha Fin: 2025-09-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-09
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2023-ACCELERATOROPEN-01:
EIC Accelerator Open 2023
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
CELTIC BIOTECH LIMITED
No se ha especificado una descripción o un objeto social para esta compañía.
